Revance Therapeutics Prices 3.25M Share Offering @$36.00/Share

Revance Therapeutics, Inc. RVNC today announced the pricing of its underwritten public offering of 3,250,000 shares of its common stock at a price to the public of $36.00 per share. Revance also granted the underwriters a 30-day option to acquire an additional 487,500 shares from Revance. The offering is expected to close on November 9, 2015, subject to customary closing conditions. Cowen and Company, LLC, Piper Jaffray & Co., and Guggenheim Securities, LLC are acting as book-running managers for the proposed offering, with William Blair & Company, L.L.C., and SunTrust Robinson Humphrey, Inc. acting as co-managers. A shelf registration statement relating to the shares was filed with the Securities and Exchange Commission on March 4, 2015 and became effective on March 18, 2015. The offering will be made only by means of a prospectus supplement. When available, copies of the preliminary prospectus supplement and accompanying prospectus relating to the proposed public offering may be obtained by contacting Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 631-274-2806, Fax: 631-254-7140; or Piper Jaffray & Co., 800 Nicollet Mall, Suite 1000, Minneapolis, MN 55402, Telephone: See full press release